Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

Nature Medicine

Volumn 6, Issue 6, 2000, Pages 667-672

  Trojan, Andreas ^a,b   Schultze, Joachim L ^a,b   Witzens, Mathias ^a,b   Vonderheide, Robert H ^a,b   Ladetto, Marco ^a,b   Donovan, John W ^a,b   Gribben, John G ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER IMMUNOLOGY; CYTOTOXIC T LYMPHOCYTE; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; PRIORITY JOURNAL; TUMOR REJECTION;

B-LYMPHOCYTES; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOGLOBULINS; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034125194     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/76243     Document Type: Article

References (45)

1. Janeway, C.A. Jr., Sakato, N. & Eisen, H.N. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc. Natl. Acad. Sci. USA 72, 2357-2360 (1975).
2. Bogen, B., Malissen, B. & Haas, W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 16, 1373-1378 (1986).
3. Campbell, M.J. et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139, 2825-2833 (1987).
4. George, A.J., Tutt, A.L. & Stevenson, F.K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 138, 628-634 (1987).
5. Lauritzsen, G.F., Weiss, S. & Bogen, B. Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand. J. Immunol. 37, 77-85 (1993).
6. Syrengelas, A.D., Chen, T.T. & Levy, R. DNA immunization induces protective immunity against B-cell lymphoma. Nature Med. 2, 1038-1041 (1996).
7. King, C.A. et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Med. 4, 1281-1286 (1998).
8. Weiss, S. & Bogen, B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. USA 86, 282-286 (1989).
9. Weiss, S. & Bogen, B. MHC class II-restricted presentation of intracellular antigen. Cell 64, 767-776 (1991).
10. Lauritzsen, C.F., Weiss, S., Dembic, Z. & Bogen, B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. USA 91, 5700-5704 (1994).
11. Munthe, L.A., Kyte, J.A. & Bogen, B. Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo. Eur J. Immunol. 29, 4043-4052 (1999).
12. Kwak, L.W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-1215 (1992).
13. Hsu, F.J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89, 3129-3135 (1997).
14. Wen, Y.J., Ling, M. & Lim, S.H. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma. Br. J. Haematol. 100, 464-468 (1998).
15. Wen, Y.J., Ling, M., Bailey-Wood, R. & Lim, S.H. Idiotypic protein-pulsed acherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4, 957-962 (1998).
16. Wen, Y.J. & Lim, S.H. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur. J. Immunol. 27, 1043-1047 (1997).
17. Fagerberg, J. et al. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int. J. Cancer 80, 671-680 (1999).
18. Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171-1177 (1999).
19. Osterroth, F., Garbe, A., Fisch, P. & Veelken, H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 95, 1342-1349 (2000).
20. Fuchs, E.J. & Matzinger, P. B cells turn off virgin but not memory T cells. Science 258, 1156-1159 (1992).
21. Bennett, S.R., Carbone, F.R., Toy, T., Miller, J.F. & Heath, W.R. B cells directly tolerize CD8(+) T cells. J. Exp. Med. 188, 1977-1983 (1998).
22. Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A. & Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999).
23. Cao, W., Myers-Powell, B.A. & Braciale, T.J. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J. Exp. Med. 179, 195-202 (1994).
24. Sette, A. et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
25. van der Burg, S.H., Visseren, M.J., Brandt, R.M., Kast, W.M. & Melief, C.J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156, 3308-3314 (1996).
26. Savage, P.A., Boniface, J.J. & Davis, M.M. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10, 485-492 (1999).
27. Parker, K.C , Bednarek, M.A. & Coligan, J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175 (1994).
28. Gulukota, K., Sidney, J., Sette, A. & DeLisi, C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267, 1258-1267 (1997).
29. Molldrem, J. et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450-2457 (1996).
30. Nijman, H.W. et al. Identification of peptide sequences that potentially trigger HLA-A2.1 - restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23, 1215-1219 (1993).
31. Brossart, P. et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309-4317 (1999).
32. Vonderheide, R.H., Hahn, W.C., Schultze, J.L. & Nadler, L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679 (1999).
33. Parker, K.C., Shields, M., DiBrino, M., Brooks, A. & Collgan, J.E. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol. Res. 14, 34-57 (1995).
34. Schultze, J.L. et al. CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100, 2757-2765 (1997).
35. Cox, A.L. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719 (1994).
36. Wang, R.F., Appella, E., Kawakami, Y., Kang, X. & Rosenberg, S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184, 2207-2216 (1996).
37. Blake, N. et al. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791-802 (1997).
38. Schirmbeck, R., Wild, J. & Reimann, J. Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur. J. Immunol. 28, 4149-4161 (1998).
39. Kessler, B.M., Bassanini, P., Cerottini, J.C. & Luescher, I.F. Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. J. Exp. Med. 185, 629-640 (1997).
40. Pardoll, D.M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci USA 96, 5340-5342 (1999).
41. Nestle, F.O. et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
42. Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
43. Manici, S. et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189, 871-876 (1999).
44. Provan, D. et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88, 2228-2235 (1996).
45. Hawkins, R.E. et al. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83, 3279-3288 (1994).